Eisai Zonegran Generics Launch
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA approved ten generic versions of Eisai's anti-epileptic Zonegran (zonisamide) Dec. 22
You may also be interested in...
Eisai Acquires Elan's Zonegran; Will Detail With Aricept
Elan will receive a $130 mil. upfront payment and up to $110 mil. in milestone payments. Eisai does not plan to seek a co-promotion partner for the epilepsy agent.
NDAs Should Include More Cross-Study Analysis, FDA Says In Draft Guidance
FDA is clarifying that it expects sponsors to provide analysis of efficacy data rather than simply a summary of clinical data as part of the integrated summary of effectiveness in new drug applications
New Look At Ezetimibe Fails To Confirm Vytorin Cancer Signal
Interim data from SHARP and IMPROVE-IT trials fail to show evidence of impact on cancer rates.